Sucampo Pharmaceuticals, Inc. has confirmed that its partner, R-Tech Ueno, Ltd. (”RTU”) has reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings. Furthermore, although there was an irritation upon instillation, there were no severe adverse effects.

Read the full story here